Matrixyl 3000: A Trade Name for Two Peptides, Not One — Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7

What it is

Matrixyl 3000 is a trade name, and it covers two molecules, not one. A 2026 University of Nottingham study of how cosmetic actives enter skin (Trzaska et al., Int J Pharm, PMID 42790608) states the composition plainly: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR), "present in Matrixyl™ 3000".

Each is a very short peptide with a palmitoyl group — a 16-carbon fatty-acid tail — attached to its first amino acid. The tail makes the molecule more oil-loving, the usual reason given for adding it to a cosmetic peptide.

The Matrixyl names belong to the ingredient maker Sederma. The supplier's own statement of the proportions of the two peptides was not read for this entry, so none is given here.

How it differs from Matrixyl and GHK-Cu

Three ingredient names share letters and are easy to confuse. They are different molecules:

Palmitoyl tripeptide-1 and GHK-Cu share the Gly-His-Lys sequence; what is attached to it differs (a fatty tail in one, copper in the other). This table compares molecules, not products, and says nothing about which works better — no study this library found compares them.

What it is said to do

The claim made for these peptides is that short collagen-like fragments act as signals, prompting skin cells called fibroblasts to make more collagen and other matrix proteins. That claim rests on laboratory work on cells and on supplier material. What exists in people is thin:

• Where it goes. The 2026 Nottingham study applied serums containing Matrixyl 3000 to three healthy women for 0.5, 2 and 5 hours, then tape-stripped the outer skin and analysed it by mass spectrometry. Both peptides were found in every layer of the stratum corneum, with signal falling with depth and no significant change with longer exposure; the depth profiles suggested they sat on the outer surfaces of cells rather than inside them. Two of the authors are from the No7 Beauty Company (Boots). The study measured permeation, not any effect on wrinkles.
• The one record tagged as a randomised trial tested a whole eye cream. Yang and colleagues (Skin Res Technol 2024, PMID 38932444; first author from the cream's developer, Mageline Biology Tech) evaluated a cream whose "active complex" combined a yeast/rice ferment filtrate, N-acetylneuraminic acid, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, reporting gains in hydration, elasticity and ultrasound collagen density over 12 weeks. With four actives in one cream, no effect can be assigned to the two peptides.
• A single-patient case report (Cureus 2026, PMID 42500768) applied a "hyaluronic acid-niacinamide-Matrixyl serum" to both halves of one woman's face, one half with a device, and reported improvement on both sides. One person, a multi-ingredient serum and a device co-developed by one author's company: it shows nothing about the peptides alone.

Where it stands

• A cosmetic ingredient, not an approved drug anywhere this library has found. Cosmetic claims about appearance do not require the trials a medicine would.
• Published record: PubMed returns 14 records for "matrixyl", 9 for palmitoyl tripeptide-1, 6 for palmitoyl tetrapeptide-7; ClinicalTrials.gov returns 0 studies for "matrixyl" and 1 for palmitoyl tripeptide-1 (all 2026-10-27).
• What a buyer will not find in the published record is a trial of the two peptides against the same cream without them.

For what these ingredients are claimed to do on skin, PeptideGlowJournal has ingredient pages on palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7; this entry is the molecules.

Related reading

Argireline is the other cosmetic peptide most often listed beside the Matrixyl names, and collagen peptides are the far larger, food-grade fragments sold for skin and joints.